Fulcrum Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Fulcrum Therapeutics Inc (FULC) is expected to report a loss of 31 cents per share, according to an earnings preview. This information is provided by Reuters and Refinitiv.
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% Higher - What's Next?
Fulcrum Therapeutics (NASDAQ: FULC) saw its shares climb 6.5% during mid-day trading on Thursday, reaching approximately $11.65 despite significantly lower trading volume. The company holds a "Moderate Buy" consensus rating from analysts with an average price target of $19.11, though recent insider and major-holder selling has been noted. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines through epigenetic control.
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company, presents a high-risk, high-reward investment opportunity with a 74.59% potential upside according to analysts. Despite facing early-stage biotech challenges like negative EPS and free cash flow, the company is developing promising therapies for genetically defined diseases, including pociredir for sickle cell disease. Its strong pipeline, strategic collaborations, and an oversold technical indicator (RSI) contribute to a positive investor sentiment, with an average target price of $19.10.
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday
Fulcrum Therapeutics (FULC) is scheduled to release its Q4 2025 earnings before market open on Tuesday, February 24th, with analysts projecting a loss of $0.31 per share. The company has seen significant insider selling, including a major sale by Ra Capital Management, and institutional investors hold a large portion of the stock. Analysts currently have a "Moderate Buy" consensus rating with an average target price of $19.11.
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
Fulcrum Therapeutics will host a conference call and webcast on February 24, 2026, to present 12-week results from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. Pociredir is an investigational oral small-molecule inhibitor designed to increase fetal hemoglobin, which has shown dose-dependent increases in HbF and improvements in markers of hemolysis and anemia, with general tolerability across dose cohorts. Dr. Martin Steinberg, a leading hematologist specializing in sickle cell disease, will join Fulcrum management for the presentation.
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 - DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics
The Facioscapulohumeral Muscular Dystrophy (FSHD) market is projected for significant growth between 2020 and 2034, driven by increasing prevalence, awareness, and the launch of pipeline products. Key companies like Avidity Biosciences and Fulcrum Therapeutics are advancing therapies, with several clinical trial milestones and funding rounds noted for 2024 and 2025. The market analysis by DelveInsight covers epidemiology, treatment trends within the 7MM (United States, EU4, UK, Japan), and highlights promising emerging therapies.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has received a "Moderate Buy" consensus rating from ten analysts, with an average 12-month price target of $19.11. Despite this positive outlook, the company has seen significant insider and major-holder selling, including a 40.82% reduction by Ra Capital and approximately $58.7 million in insider sales over the last quarter. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines to modulate gene expression, with key programs targeting sickle cell disease, beta-thalassemia, and facioscapulohumeral muscular dystrophy.
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Shares of Fulcrum Therapeutics (FULC) have seen a 4.9% gain recently, with Wall Street analysts projecting a potential upside of 75.7% based on a mean price target of $19.1. Despite the optimism, the article cautions investors that price targets can often be misleading and should be viewed with skepticism, though a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for FULC provide stronger indications of potential upside.
Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
Shares of Fulcrum Therapeutics (FULC) recently closed at $10.87, and Wall Street analysts predict a mean price target of $19.1, suggesting a potential upside of 75.7%. However, investors are cautioned that price targets can be misleading, and a low standard deviation in estimates indicates a higher agreement among analysts. The company's strong Zacks Rank #2 (Buy) and positive revisions in earnings estimates further support potential near-term upside.
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies
This report from DelveInsight offers a comprehensive overview of the Facioscapulohumeral Muscular Dystrophy (FSHD) pipeline, detailing over 10 key companies and 12+ treatment therapies in various stages of clinical development. It highlights major market players like Dyne Therapeutics, Avidity Biosciences, and Fulcrum Therapeutics, and emerging therapies such as DYNE-301, MC-DX4, and Losmapimod. The report also covers recent clinical trial advancements, funding, and regulatory progress, emphasizing the growing efforts to develop effective treatments for FSHD.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. announced it granted non-statutory stock options to one new employee under its 2022 Inducement Stock Incentive Plan. This grant, involving 70,000 options at an exercise price of $10.72, was made to induce the employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, subject to continued service.
Insider Sell: Robert Gould Sells 15,000 Shares of Fulcrum Therapeutics Inc (FULC)
Robert Gould, a Director at Fulcrum Therapeutics Inc (FULC), sold 15,000 shares of the company on February 2, 2026, reducing his total holdings to 454,864 shares. This transaction is part of a trend over the past year where Gould has sold a total of 60,000 shares with no buys, and the company has seen 7 insider sells versus 0 buys. Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, is currently considered a "Possible Value Trap, Think Twice" by GuruFocus, with a price-to-GF-Value ratio of 0.29 given its $10.72 stock price against a GF Value of $36.72.
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: An Ambitious Biotech with 92.93% Upside Potential
Fulcrum Therapeutics (FULC) is a clinical-stage biopharmaceutical company focused on genetically defined diseases, with a significant 92.93% potential upside according to analysts. Despite current negative financial metrics typical of R&D-heavy biotech firms, the company's flagship product, pociredir, and collaborations with industry giants position it for future growth. Investors should weigh the high potential rewards against the inherent volatility and uncertainty of biotechnology investments.
Campbell & CO Investment Adviser LLC Takes Position in Fulcrum Therapeutics, Inc. $FULC
Campbell & CO Investment Adviser LLC has initiated a new position in Fulcrum Therapeutics (NASDAQ:FULC) by acquiring 102,470 shares valued at approximately $943,000, representing 0.19% ownership. This move comes amidst significant insider selling, with Ra Capital Management notably reducing its stake by over 40% and other insiders selling around 4.2 million shares in the past 90 days. Despite insider selling, analysts maintain a "Moderate Buy" consensus with a $19.11 price target, with some firms raising targets up to $25.
Fulcrum Therapeutics (NASDAQ:FULC) Cut to Sell at Wall Street Zen
Wall Street Zen downgraded Fulcrum Therapeutics (NASDAQ:FULC) from "hold" to "sell." This downgrade follows significant insider selling, including a major shareholder cutting its stake by over 40%, and the company missing its last EPS estimates. Despite these negative indicators, the stock trades around $10.14, while analysts maintain a "Moderate Buy" consensus with an average price target of $19.11.
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating
Truist Financial analyst Gregory Renza has reiterated a Buy rating on Fulcrum Therapeutics (FULC.US). The analyst's past performance shows a 50.2% success rate and an average return of 23.2% over the last year, according to TipRanks data. This information is intended for informational purposes only and does not constitute investment advice.
This Netflix Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts have initiated coverage on five companies, including Netflix Inc., Medline Inc., Hims & Hers Health Inc., Andersen Group Inc., and Fulcrum Therapeutics Inc. Netflix received a Buy rating with a $107 price target from HSBC. The other companies also saw new coverage with Outperform, In-Line, Overweight, and Buy ratings respectively from various banks.
JPMorgan Initiates Coverage on Fulcrum Therapeutics With Overweight Rating, $20 Price Target
JPMorgan has initiated coverage on Fulcrum Therapeutics (NASDAQ: FULC) with an "Overweight" rating and a price target of $20. The biopharmaceutical company focuses on genetically defined rare diseases and has product candidates like losmapimod for FSHD and FTX-6058 (pociredir) for sickle cell disease. This positive analyst rating comes amidst recent news including clinical trial results and stock offerings.
JP Morgan Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight Recommendation
JP Morgan has initiated coverage of Fulcrum Therapeutics (FULC) with an Overweight recommendation. Analysts project a potential 96.75% upside with an average one-year price target of $19.38/share. The article also details institutional ownership, fund sentiment, and key shareholder positions, indicating a bullish outlook for the company.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics, Inc. announced it granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. This comes as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of 30,400 shares at an exercise price of $10.84 per share, vesting over four years.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics announced that it granted non-statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan. These grants, totaling 30,400 options at an exercise price of $10.84 per share, are an inducement for their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The options vest over four years, with a ten-year term, subject to continued service.
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Company management will present on January 14, 2026, to discuss their work on developing small molecules for genetically defined rare diseases, including their lead program pociredir for sickle cell disease. A live webcast and replay will be available for interested parties.
Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould Sells 15,000 Shares
Fulcrum Therapeutics (NASDAQ:FULC) Director Robert Gould sold 15,000 shares of the company's stock for a total of $178,050.00 on January 2, 2026, reducing his stake by 3.09%. Following the sale, Fulcrum Therapeutics' shares traded down 7.8% to $9.99, with the company currently having a market cap of $540.6 million and a consensus analyst "Hold" rating with an average target price of $19.00. The company recently missed its quarterly EPS estimates and institutional ownership stands at 89.83%.
Los Angeles Daily News - Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will present on January 14, 2026, discussing the company's work in developing small molecules for genetically defined rare diseases, including their lead program pociredir for sickle cell disease. A live webcast and replay will be available on their website.
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics, Inc. announced its management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of the presentation will be available on their website. The company focuses on developing small molecules for genetically defined rare diseases.
Fulcrum Therapeutics (NASDAQ:FULC) Trading Down 4.3% - Time to Sell?
Fulcrum Therapeutics (NASDAQ:FULC) shares fell 4.3% on Tuesday, trading at $11.48 with significantly reduced volume. Analyst sentiment for FULC is mixed, with a consensus "Hold" rating and a $19 target, while some analysts have raised targets to $25. The article also highlights substantial insider selling, with RA Capital Management reducing its stake by over 40% and insiders holding approximately 7% of the company.
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
Wall Street analysts project a significant upside for Fulcrum Therapeutics (FULC), with a mean price target suggesting a 58.5% surge. This optimism is supported by strong agreement on earnings estimate revisions, despite general skepticism surrounding analyst price targets. Investors are advised to consider the high standard deviation in targets and use this information as a starting point for further research.
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
Wall Street analysts project Fulcrum Therapeutics (FULC) could see a 58.47% surge, with a mean price target of $19.00 among nine short-term estimates. Despite the potential for misleading information in price targets, strong agreement among analysts and positive earnings estimate revisions, indicated by a Zacks Rank #2 (Buy), suggest a potential upside for the stock. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Hold" by Analysts
Fulcrum Therapeutics (NASDAQ:FULC) has received a consensus "Hold" rating from eleven research firms, with an average 12-month target price of $19.00 despite several recent upgrades from analysts. The company has seen significant insider selling, including a major shareholder reducing their stake, and reported a recent quarterly EPS miss. Shares opened at $12.00, with a market capitalization of $649.15 million.
Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 5.7% - Should You Sell?
Fulcrum Therapeutics (NASDAQ:FULC) shares dropped 5.7% during mid-day trading on Tuesday, with significantly lower trading volume than average. The company currently holds a "Hold" consensus rating from analysts, with a diverse range of price targets. Recent insider selling, particularly by major shareholder Ra Capital Management, has reduced insider ownership to about 7%, while institutional investors hold nearly 90%.
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Analyst sentiment for Fulcrum Therapeutics (FULC) is turning bullish after positive updates from its Phase 1b PIONEER study of pociredir for sickle cell disease. Truist raised its price target to $18, citing strong data, while Bank of America also increased its target but maintained an "Underperform" rating. The company's recent public offering raised $175 million to bolster its balance sheet.
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Analyst sentiment for Fulcrum Therapeutics (FULC) is growing following positive updates from its Phase 1b PIONEER study of pociredir in sickle cell disease, with 80% of analysts bullish and a median price target of $18. Truist and Bank of America both raised their price targets on FULC after initial results showed robust increases in fetal hemoglobin and a favorable safety profile. The company also recently priced a public offering to raise $175 million to enhance balance sheet flexibility.
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Analyst sentiment for Fulcrum Therapeutics (FULC) is growing bullish after positive updates from its Phase 1b PIONEER study of pociredir for sickle cell disease. Truist and Bank of America have both updated their price targets, and the company completed a public offering to raise $175 million. These developments highlight pociredir's potential as a once-daily oral therapy with a favorable safety profile.
Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study
Analyst sentiment for Fulcrum Therapeutics (NASDAQ: FULC) is growing bullish after positive updates from the Phase 1b PIONEER study for sickle cell disease. Truist raised its price target to $18 with a "Buy" rating, while Bank of America increased its target to $7, reiterating an "Underperform" rating. These developments, along with a recent public offering, reinforce the potential of pociredir as a once-daily oral therapy.
Fulcrum Therapeutics (FULC) Price Target Increased by 32.56% to 19.38
The average one-year price target for Fulcrum Therapeutics (NasdaqGM:FULC) has been raised by 32.56% to $19.38 per share, up from $14.62. This new target represents a 57.82% increase from the last closing price of $12.28 per share. Institutional ownership data shows 267 funds holding positions in FULC, with a slight decrease in total shares owned by institutions over the last quarter, yet indicating a bullish outlook with a put/call ratio of 0.60.
Fulcrum Therapeutics prices $175 million public offering
Fulcrum Therapeutics (NASDAQ:FULC) announced the pricing of a public offering valued at approximately $175 million, comprising 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants. This capital raise, which follows strong stock performance and recent positive clinical trial results for its sickle cell disease treatment, pociredir, is intended for general corporate purposes including research and development and clinical trials. Analysts from Stifel and Goldman Sachs have responded positively to the company's prospects, while BofA Securities adjusted its price target for the stock.
Truist Securities Maintains Fulcrum Therapeutics (FULC) Buy Recommendation
Truist Securities reaffirmed its Buy recommendation for Fulcrum Therapeutics (FULC) on December 11, 2025. The average one-year price target for FULC is $14.62, suggesting a potential 14.26% upside from its last closing price of $12.80. Institutional ownership shows a slight decrease in total shares, although some major funds have increased their positions.
Fulcrum Therapeutics announces proposed $150.0 million public offering of common stock
Fulcrum Therapeutics has announced a proposed public offering of $150.0 million in common stock. This move is detailed in the press release and indicates the company's intention to raise capital through the stock market.
Ra Capital Management, L.P. Sells 4,175,139 Shares of Fulcrum Therapeutics (NASDAQ:FULC) Stock
Ra Capital Management, L.P. sold over 4.1 million shares of Fulcrum Therapeutics (NASDAQ:FULC) stock for approximately $58.37 million, reducing its stake by 40.82%. This transaction leaves Ra Capital Management with 6,053,960 shares in the company, currently valued at around $84.63 million. Following the news, Fulcrum Therapeutics' stock experienced a 5.5% drop on heavy trading.
FULC: Truist Securities Raises Price Target for Fulcrum Therapeu
Truist Securities has raised its price target for Fulcrum Therapeutics (FULC) by 28.57% to $18.00, maintaining a "Buy" rating. This follows several other analysts updating their ratings for FULC, with the average target price from nine analysts now at $18.56, implying a 43.07% upside. Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focusing on treatments for FSHD and sickle cell disease.
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants
Fulcrum Therapeutics has announced the pricing of an upsized public offering of common stock and pre-funded warrants, aiming to raise $175 million. This offering is intended to provide the company with additional capital.
Ra capital sells Fulcrum Therapeutics (FULC) shares for $58.3 million
RA Capital Management and associated parties sold Fulcrum Therapeutics (FULC) common stock totaling $58.3 million on December 8, 2025. This sale occurred after FULC shares surged significantly over the past week and year, with InvestingPro indicating the stock is overbought and potentially overvalued despite positive recent developments like an upsized public offering and a raised price target from Stifel due to strong trial data.
Fulcrum Therapeutics stock falls after pricing $175 million public offering
Fulcrum Therapeutics (NASDAQ:FULC) stock fell 5% after the clinical-stage biopharmaceutical company priced an upsized public offering of common stock and pre-funded warrants worth $175.0 million. This decline follows a 12% surge in shares the previous day due to positive results from its sickle cell drug trial. The dip suggests investor concern over potential share dilution from the new offering, which includes 11,851,853 shares of common stock and 1,111,193 pre-funded warrants.
Fulcrum Therapeutics (Nasdaq: FULC) sets $13.50 price for 11,851,853-share equity sale
Fulcrum Therapeutics priced an upsized public offering to raise approximately $175.0 million by selling 11,851,853 shares of common stock at $13.50 per share and 1,111,193 pre-funded warrants at $13.499 each. The net proceeds are primarily for general corporate purposes, including R&D and clinical trials. The offering is expected to close around December 11, 2025.
Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics has announced the pricing of a $175 million public offering of common stock and pre-funded warrants. The offering involves 11,851,853 shares at $13.50 per share and 1,111,193 pre-funded warrants at $13.499 each, with proceeds allocated for general corporate purposes including R&D for clinical programs like its sickle cell disease treatment, pociredir. The offering grants underwriters a 30-day option for additional shares and is expected to close on December 11, 2025.
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
Fulcrum Therapeutics has announced the pricing of an upsized public offering totaling $175.0 million. The offering includes 11,851,853 shares of common stock at $13.50 per share and pre-funded warrants for 1,111,193 shares at $13.499 per warrant. The net proceeds are intended for general corporate purposes, including R&D, clinical trials, and potential acquisitions.
B of A Securities Maintains Fulcrum Therapeutics (FULC) Underperform Recommendation
B of A Securities maintained an Underperform recommendation for Fulcrum Therapeutics (FULC) on December 9, 2025, according to a report by Fintel. The average one-year price target is $14.62, suggesting a 12.55% upside from its last closing price of $12.99. Institutional ownership indicates a slight decrease in shares owned over the last three months, though several funds increased their portfolio allocation.
Fulcrum Therapeutics shares rise after positive phase 1b sickle cell trial results
Fulcrum Therapeutics (NASDAQ:FULC) stock increased following positive interim results from its Phase 1b trial for FTX-6058 in sickle cell disease patients. The study showed FTX-6058 was well-tolerated and produced dose-dependent increases in fetal hemoglobin, a key biomarker for therapeutic efficacy in sickle cell treatment. The promising data supports continued development of FTX-6058 as a potential treatment option.
Fulcrum Therapeutics (FULC): Valuation Check After PIONEER Trial Success and Follow-On Offering
Fulcrum Therapeutics' (FULC) share price surged following positive early PIONEER trial data for pociredir, which showed meaningful fetal hemoglobin gains in sickle cell patients. Despite the positive news and a significant increase in share price, the stock's valuation on a price-to-book basis (3.5x) suggests it is cheaper than close peers but richer than the broader pharma industry. Investors are now tasked with determining if the company is still undervalued or if the market has already factored in future growth.
Fulcrum Therapeutics (FULC) Launches $150M Public Stock Offering
Fulcrum Therapeutics (FULC) is launching a $150 million public stock offering to raise capital, enlisting several financial institutions to manage the sale. The biotechnology company focuses on treatments for muscular dystrophy and hemoglobinopathies, demonstrating strong balance sheet health despite challenges in profitability. The offering aims to support its clinical development programs.
